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ABSTRACT
Objective: To investigate trends in time to invasive
examination and treatment for patient with first time
diagnosis of non-ST elevation myocardial infarction
(NSTEMI) and unstable angina during the period from
2001 to 2009 in Denmark.
Design: From 1 January 2001 to 31 December 2009 all
first time hospitalisations with NSTEMI and unstable
angina were identified in the National Patient Registry
(n=65 909). Time from admission to initiation of
coronary angiography (CAG), percutaneous coronary
intervention (PCI) or coronary artery bypass graft (CABG)
was calculated. We described the development in invasive
examination and treatment probability (CAG, PCI and
CABG at 3, 7, 10, 30 and 60 days) for the years
2001–2009, taking the competing risk of death into
account using Aalen–Johansen estimators and a Fine-
Gray model.
Setting: Nationwide Danish cohort.
Results: The proportion of patients receiving a CAG and
PCI increased substantially over time while the proportion
receiving a CABG decreased for both NSTEMI and
unstable angina. For both NSTEMI and unstable angina, a
significant increase in invasive examination and treatment
probability at 3 days for CAG and PCI were seen
especially from 2007 through to 2009. For NSTEMI, the
CAG examination probability at 3 days leaped from 20%
in 2007 to 32% in 2008 and 39% in 2009, and for PCI
the same was true with a leap in treatment probability
from 19% to 28% from 2008 to 2009.
Conclusions: In Denmark the use of CAG and PCI in
treatment of NSTEMI and unstable angina has increased
from 2001 to 2009, while the use of CABG has
decreased. During the same period, there was a marked
increase in invasive examination and treatment probability
at 3 days, that is, more patients were treated faster which
is in line with the political aim of reducing time to
treatment.
INTRODUCTION
Treatment of acute coronary heart disease
has advanced substantially during the latest
decades, and improved clinical outcome has
been seen.1 A recent register-based Danish
cohort study by Schmidt et al2 found that
short-term mortality after ﬁrst time hospital-
isation with acute myocardial infarction
(AMI) was nearly halved from 1984 to 2008.
It has been suggested that part of this
decline can be attributed to improved treat-
ment including introduction of thrombolysis,
coronary artery bypass grafting (CABG), per-
cutaneous coronary intervention (PCI) and
improved medical prevention after diagno-
sis.3 Coronary angiography (CAG) is recom-
mended as part of the diagnostic process for
all patients with AMI with PCI as the primary
intervention.4 Since the mid-1990s, there has
been a strong political focus on time to treat-
ment in order to reduce case fatality.5 For
coronary heart disease, this focus in
Denmark has among other initiatives led to
the development of ﬁxed treatment proto-
cols for patients with non-ST elevation myo-
cardial infarction (NSTEMI) and unstable
angina. These protocols were implemented
during 2009. The protocol stipulates that the
maximum time from admission with
NSTEMI to invasive examination (CAG)
Strengths and limitations of this study
▪ Large unselected patient population n=65 909.
▪ Detailed register-based data.
▪ Use of statistical methods that account for com-
peting risks.
▪ Information on extension and severity of the
disease.
▪ No information on biomarkers to validate register-
based data.
▪ No information on why patients died without
treatment.
Mårtensson S, Gyrd-Hansen D, Prescott E, et al. BMJ Open 2014;4:e004052. doi:10.1136/bmjopen-2013-004052 1
Open Access Research
should be less than 3 calendar-days (72 h) and time to
appropriate invasive treatment less than 3 calendar-days
for PCI and 7 calendar-days for CABG.6 These protocols
are based on the shared European guidelines.4 7
The purpose of this study was to investigate a potential
explanation of the signiﬁcant improvement in prognosis
by describing time to invasive examination and treat-
ment for patients with ﬁrst-time diagnosis of NSTEMI or
unstable angina during the period from 2001 to 2009 in
Denmark using a nationwide cohort design and taking
into account vessel disease severity as well as using
appropriate methods of analysis that account for the
competing risk of death. This study is the ﬁrst nation-
wide cohort study to describe time waited for CAG, PCI
and CABG over a decade where large changes in treat-
ment of NSTEMI and unstable angina were introduced
including the introduction of ﬁxed treatment protocols.
METHOD
The Danish healthcare system provides universal cover-
age for all citizens. Since 1995, all contacts with the
healthcare system including emergency, ambulatory and
inpatient have been registered in the National Patient
Registry (NPR) with information about time and date of
admission and discharge along with information about
diagnosis as well as type and date of potential invasive
treatment or examination.8 Furthermore, there are
several registers and clinical quality databases with
patient-speciﬁc information9 that can be linked with the
data from the NPR through the use of the unique
10-digit person identiﬁer. The registers used for this
study are the NPR, the Danish Heart Registry, which reg-
isters information regarding patients undergoing inva-
sive cardiac procedure10 and the Medical Cause of
Death Registry, which contains information on time and
cause of death.11
Study population
From 1 January 2001 to 31 December 2009 all ﬁrst time
hospitalisations of acute coronary heart syndrome (ACS)
were identiﬁed in the NPR (n=99 473) by the following
International Classiﬁcation of Diseases (ICD) 10 codes
(I20.0 Unstable angina pectoris, I21.0–I21.3 ST elevation
myocardial infarction (STEMI), 121.4 NSTEMI and
I21.9 AMI—unspeciﬁed) using discharge diagnoses (see
ﬁgure 1). Patients with prior heart disease (ICD10: I20–
I25) were excluded using information from the NPR
going back to 1995 (n=19 440) leaving 80 033 patients. A
previous study by Joensen et al12 found that the ACS
diagnosis registered in the NPR should be used with
caution especially the unstable angina diagnosis.
Joensen et al recommend restricting the analysis to
patients discharged from wards when another validation
is not possible. We therefore excluded outpatients
(n=2564) and patients with an NSTEMI or unstable
angina diagnosis from an emergency room that was not
veriﬁed in the subsequent admission (n=11 560), still
allowing for a shift from NSTEMI to unstable angina or
vice versa. Consequently, the ﬁnal population consisted
of 65 909 patients. Diagnosis can change after the result
of CAG; therefore, we used the diagnosis registered after
the CAG in the analysis of time to PCI and CABG. For
this reason the number of patients in the different sub-
diagnosis groups varies between analyses of CAG, PCI
and CABG (see ﬁgure 1 for distribution of patients with
ACS in subdiagnosis groups at initial examination and
after CAG). Patients with STEMI and unspeciﬁed myo-
cardial infarction (MI) are only included in the initial
descriptive analysis of the patient population.
Variables
Time to examination or treatment (from admission to CAG,
PCI and CABG)
Time (measured in hours) from admission to initiation
of CAG, PCI or CABG was calculated using information
from the NPR (the speciﬁc SKS codes can be seen in
online supplementary appendix 1). Only treatment and
examination within the ﬁrst 60 days after initial symptom
presentation were included. Further information regard-
ing this variable can be found in the online supplemen-
tary appendix 2.
Severity and extent of disease
Severity and the extent of disease will inﬂuence the per-
ceived urgency of treatment. Information on the
number of occluded vessels and left main coronary
artery (LMCA) involvement was available from the
Danish Heart Register (DHR) in 82.1% and 84.7% of
the cases that received a CAG, respectively. We allowed
for a slip of ±2 days between NPR CAG date and DHR
CAG date when identifying CAG information.
Other covariates include sex, age and year of diagnosis.
Statistical methods
In the descriptive analysis, the number of patients receiv-
ing CAG, PCI or CABG was reported along with the
number of patients receiving the respective examination
or treatment within 3 days for CAG and PCI and 7 days
from CAG for CABG for each diagnosis and for each of
the covariates: age, sex, number of occluded vessels and
LMCA involvement. When investigating time to treat-
ment for a speciﬁc disease, it is important to account for
the competing risk of death in order to account for the
time waited by patients who die before they are
treated.13 Reporting a median time to treatment is not
relevant as it will only describe the time waited by
patients who manage to be treated. Furthermore, if we
wish to model cumulated probability of treatment (not
intensities) and applied standard methods (eg, Cox
regression method or Kaplan–Meier plots), then we
would regard death without treatment as independent
censoring and would only be able to make inference for
a hypothetical population where patients do not die
without being treated.13 The problem of competing risks
is especially important for a potentially fatal disease like
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ACS where some subdiagnosis has a relative high mortal-
ity rate.14 15 Furthermore, as ﬁrst-line invasive treatments
are mutually exclusive (patients receive either PCI or
CABG), we need to account for the competing risk of
receiving the other treatment, respectively. To account
for this competing risk problem, we used
Aalen-Johansen plots where we described the develop-
ment in invasive examination (CAG) and treatment
probability (PCI and CABG) for the years 2001–2009.
These plots account for the competing risks of death
and treatment (PCI or CABG, respectively) by showing
the estimated percentage of the original population,
which at a given time has received the examination
(CAG) and treatment (PCI or CABG). The plot has no
distributional assumptions.13 From these plots we
derived probability at 1, 3, 7 (only for CABG), 10, 30
and 60 days after diagnosis. These probabilities are pre-
sented in graphs in order to show the development
from 2001 to 2009.
To test whether the effects seen in the plots were statis-
tically signiﬁcant, we used the Fine-Gray model, a regres-
sion model that accounts for competing risks and adjusts
for covariates.13 In this model we ﬁnd the effect of the
calendar years when controlling for covariates (age, sex,
LMCA involvement and number of occluded vessels).
When analysing the impact of the ﬁxed treatment
protocols implemented during 2009, a proper evalu-
ation with a control group was not feasible due to lack
of an appropriate comparison group. Consequently we
applied a second-best solution where we looked at
whether the change in times to examination or treat-
ment in the year 2009 differed from the time trend
observed in the time period from 2001 to 2008 extrapo-
lated to 2009. The use of this method was inspired by
the methods used by Lee et al16 when evaluating the
effects of Pay for Performance in the UK. We tested
this in the Fine-Gray model and report the test statistics
as z. Year 2001 is the reference when year is included
Figure 1 Flow chart of patient population.
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categorically. In all analyses, a 5% signiﬁcance level was
used.
Data were analysed with SAS V.9.3, STATA V.12.1 and
by using the macro COMPRISK to draw Aalen-Johansen
plot provided open access by the MAYO Institute.
RESULTS
Of the 65 909 patients identiﬁed, 28.7% were admitted
with NSTEMI, 13.4% with unstable angina, 25.5% with
STEMI and 32.4% with non-speciﬁed MI. A total of 8412
patients were after the CAG registered with a non-ACS
diagnosis and subsequently excluded from further ana-
lysis of PCI and CABG (see online supplementary
appendix 3 where the diagnoses that account for 80% of
these patients are listed). After CAG, the distribution of
diagnosis was as follows: 35% of patients were admitted
with NSTEMI, 12.6% with unstable angina, 33.2 with
STEMI and 19.2 with non-speciﬁc MI.
Table 1 show that from 2001 to 2009, the proportion
of patients with NSTEMI receiving a CAG and PCI
increased substantially, while the proportion receiving a
CABG decreased. During the same period, the fraction
of patients examined with a CAG who received this
within 3 days increased from 18.2% to 55.7%. For PCI a
similar development was seen with 52% treated within
3 days in 2009 compared with 27.5% treated in 2001.
For CABG, within 7 days the percentage slightly declined
over the time period with some ﬂuctuations.
For unstable angina, the activity rate increased for
CAG, but not for PCI in the period from 2001 to 2009
(table 2); however, for both CAG and PCI the rates of
Table 1 CAG, PCI and CABG treatment rates and number of patients treated within 3/7 days distributed according to
covariates for patients with first time NSTEMI
NSTEMI
Diagnosis at initial examination Diagnosis registered after CAG
CAG within 60 days
PCI within 60 days (grouped
according to after CAG
diagnosis)
CABG within 60 days from
CAG
Examination
rate (%) n
Per cent
in 3 days*
Treatment
rate (%) n
Per cent
in 3 days*
Treatment
rate (%) n
Per cent
in 7 days*
Overall
18.947 63.3 11 997 31.8 52.7 5984 30.7 16.2 1836 26.3
Year of diagnosis
2001 49.8 823 18.2 48.4 255 27.5 23.0 121 29.5
2002 54.9 1177 19.9 49.6 465 24.8 22.8 214 23.7
2003 58.7 1355 26.2 51.4 597 21.2 19.5 226 38.5
2004 61.3 1422 23.2 54.3 673 24.2 17.8 221 35.5
2005 67.7 1480 26.6 56.7 771 23.7 16.2 220 25.7
2006 68.0 1401 28.9 55.1 792 24.6 13.1 188 23.3
2007 66.9 1438 30.7 49.5 728 27.4 16.5 243 15.3
2008 70.5 1533 46.2 50.3 817 38.9 13.2 214 24.7
2009 70.0 1368 55.7 55.3 886 52.0 11.8 189 23.0
Gender
Men 70.8 8072 32.3 56.3 4247 30.8 18.8 1424 25.7
Women 52.1 3791 29.4 47.0 1615 26.9 11.2 386 28.0
Age
30 or younger 86.7 26 37.5 15.0 3 66.7 – – –
30–39 91.5 225 44.3 53.1 111 42.9 2.3 5 60.0
40–49 91.4 1093 40.6 59.2 599 42.2 7.0 72 33.8
50–59 89.4 2521 33.2 61.0 1459 29.8 12.5 302 28.3
60–69 84.0 3543 29.8 52.5 1703 28.3 20.8 675 25.6
70–79 66.1 3337 27.6 47.9 1472 25.9 21.7 665 23.7
80 or older 21.8 1118 31.2 49.7 515 27.5 8.7 91 33.3
LMCA involvement
Yes 18.7 39 33.3 65.6 137 50.4
No 54.6 4885 32.1 14.3 1276 24.9
Number of occluded vessels
0 1.9 22 31.8 0.3 4 50.0
1 78.5 2592 36.2 1.5 49 36.7
2 71.7 1393 32.0 12.7 246 23.4
3 30.0 630 30.1 49.3 1034 29.6
*National guidelines recommend CAG and PCI within 3 days of diagnosis and CABG within 7 days of CAG.
CABG, coronary artery bypass grafting; CAG, coronary angiography; LMCA, left main coronary artery; NSTEMI, non-ST elevation myocardial
infarction; PCI, percutaneous coronary intervention.
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patients who received these procedures within 3 days
doubled in this time period. For CABG the treatment
rate was more than halved.
Figure 2A shows the development in the probability of
invasive examination using CAG from 2001 to 2009 for
NSTEMI accounting for the competing risk of death. The
ﬁgure shows a signiﬁcant increase in the use of CAG in
the period from 2001 to 2005 with an increase in probabil-
ity from 49.8% for CAG at 60 days in 2001 to 70.4% in
2005 (tested using the Fine–Gray model, see results in
online supplementary appendix 4). From 2005 onwards
only a slight increase in probability of CAG at 60 days was
seen. The ﬁgure also shows a steady increase in the prob-
ability of CAG within 3 days from 2001 to 2007 followed by
a leap from 19.5% in 2007 to 31.9% in 2008 and a further
increase to 38.7% in 2009. The ﬁxed treatment protocol
seemed to have a signiﬁcant effect on the probability of
receiving a CAG within 3 days (z=4.16; p<0.001). For PCI
(ﬁgure 2B), there was only a slight increase in the prob-
ability of treatment with PCI at 60 days from 2001 to 2009.
Further, the probability of PCI treatment within 3 days
increased markedly from 2007 to 2008 and again from
2008 to 2009. The effect of the implementation of the
ﬁxed treatment protocols also revealed a signiﬁcant effect
for PCI (z=7.44; p<0.001). For CABG the development in
the treatment probability was somewhat different with a
signiﬁcant drop in probability of receiving this type of inva-
sive treatment over the period 2001–2006 with subsequent
stagnation (ﬁgure 2C). The probability of CABG within
7 days of CAG decreased signiﬁcantly over the period and
there seemed to be no effect of the ﬁxed treatment proto-
cols (z=0.50; p=0.62).
Table 2 CAG, PCI and CABG treatment rates and number of patients treated within 3/7 days distributed according to
covariates for patients with first time unstable angina
Unstable
angina
Diagnosis at initial examination Diagnosis registered after CAG
CAG within 60 days
PCI within 60 days (grouped
according to after CAG
diagnosis)
CABG within 60 days from
CAG
Examination
rate (%) n
Per cent
in 3 days*
Treatment
rate (%) n
Per cent
in 3 days*
Treatment
rate (%) n
Per cent
in 7 days*
Overall
8820 71.4 6300 44.2 49.7 2031 38.9 18.0 735 43.7
Year of diagnosis
2001 59.9 631 30.2 51.3 224 24.9 26.8 117 47.2
2002 61.0 649 32.0 47.6 200 31.2 28.8 121 44.5
2003 64.5 633 37.1 49.5 206 33.5 22.8 95 55.3
2004 72.3 663 33.1 43.4 170 23.3 20.4 80 53.4
2005 74.1 705 43.1 51.2 229 38.1 14.5 65 36.7
2006 74.3 753 44.6 52.3 228 39.9 14.0 61 42.1
2007 78.3 720 51.9 49.2 214 43.0 15.9 69 30.0
2008 82.1 823 55.5 50.4 317 52.6 11.6 73 42.0
2009 79.0 723 62.0 50.9 243 51.1 11.3 54 29.2
Gender
Men 74.9 3719 44.6 51.6 1318 39.5 21.4 549 44.1
Women 66.7 2305 37.7 48.2 658 33.4 12.0 166 41.7
Age
30 or younger 64.3 18 61.1 – – – 14.3 1 0
30–39 71.4 177 43.0 39.1 34 52.9 4.5 4 25.0
40–49 75.6 684 43.7 49.5 207 45.8 7.3 31 50.0
50–59 80.4 1562 40.0 54.0 534 39.9 13.8 137 37.0
60–69 78.3 1841 42.7 50.3 609 36.1 21.8 265 46.7
70–79 70.7 1350 40.8 46.9 429 32.3 26.7 244 42.7
80 or older 37.8 392 45.8 55.3 163 34.7 11.0 33 50.0
LMCA involvement
Yes 14.8 21 47.6 75.4 107 60.0
No 52.6 1684 39.7 15.5 496 39.8
Number of occluded vessels
0 1.9 11 50.0 0.5 3 0
1 79.1 1010 44.1 2.3 30 40.0
2 67.1 451 36.7 19.6 132 42.3
3 26.5 186 31.8 58.3 409 43.8
*National guidelines recommend CAG and PCI within 3 days of diagnosis and CABG within 7 days of CAG.
CABG, coronary artery bypass grafting; CAG, coronary angiography; LMCA, left main coronary artery; NSTEMI, non-ST elevation myocardial
infarction; PCI, percutaneous coronary intervention.
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Figure 3 shows similar graphs for patients with unstable
angina. In general, the development was very similar to that
of patients with NSTEMI, but with the increase in the inva-
sive examination and treatment rate later in the observation
period (from 2004 to 2008). The probability of receiving
CAG within 3 days increased threefold from 2001 to 2009
with an almost constant increase (ﬁgure 3A). We saw no
effect of the ﬁxed treatment protocols on timing of CAG
(z=−0.50; p=0.62). The PCI treatment rate at 60 days was
somewhat stable in the time period with a small drop in
2004, while the probability of treatment within 3 days
increased almost constantly from 2001 to 2009. There was
no effect of the ﬁxed treatment protocols (z=−0.32; p=0.75;
ﬁgure 3B). For CABG the treatment probability at 60 days
decreased in the time period as well as the treatment prob-
ability at 7 days (ﬁgure 3C). There was no signiﬁcant effect
of the ﬁxed treatment protocols. For both NSTEMI and
unstable angina, there was no signiﬁcant development in
death before treatment over time, that is, a competing risk
(analysis not shown).
Figure 2 Development in
coronary angiography (CAG),
percutaneous coronary
intervention (PCI) and coronary
artery bypass grafting (CABG)
treatment probability from 2001 to
2009 for patients with Non ST
elevation myocardial infarction at
day 1, 3, 7 (CABG only), 10, 30
and 60.
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When including age, sex, number of occluded vessels
and LMCA involvement (last 2 only for PCI and CABG),
we found that for NSTEMI the development in CAG
examination probability at 3 days and 60 days was the
same as seen in the unadjusted analyses, and the effect
of the ﬁxed treatment protocols remained signiﬁcant.
For PCI, the same pattern was observed; however, when
adjusting for the number of occluded vessels, the linear
effect of year became insigniﬁcant, but the effect of the
ﬁxed treatment protocols remained. For CABG, the
picture did not change after the adjustment except that
the decrease in treatment probability seen at 60 days was
not as noticeable as in the unadjusted analysis.
Performing the same adjustments did not change the
conclusions for unstable angina either (see all results
from the Fine-Gray model in online supplementary
appendix 5).
DISCUSSION
In this nationwide cohort study, we found a signiﬁcant
increase in the proportions of patients with NSTEMI
Figure 3 Development in
coronary angiography (CAG),
percutaneous coronary
intervention (PCI) and coronary
artery bypass grafting (CABG)
treatment probability from 2001 to
2009 for patients with unstable
angina at day 1, 3, 7 (CABG
only), 10, 30 and 60.
Mårtensson S, Gyrd-Hansen D, Prescott E, et al. BMJ Open 2014;4:e004052. doi:10.1136/bmjopen-2013-004052 7
Open Access
and unstable angina receiving a CAG and PCI in
Denmark between 2001 and 2009, while the proportion
receiving CABG decreased. In the analysis accounting
for competing risks, there was an increase in the prob-
ability of examination and treatment within 3 days for
CAG and PCI after 2001, and there seemed to be a sig-
niﬁcant effect of the introduction of a ﬁxed treatment
protocol with recommended maximum time from diag-
nosis to invasive examination and treatment for
NSTEMI, but not for unstable angina.
Our results are in agreement with studies from the USA,
which showed an increase in the use of CAG and PCI over
the past two decades, and a decrease in CABG.1 17 18 The
study also contributes to the interpretation of the ﬁndings
from a recent Danish study,2 which showed a signiﬁcant
reduction in 30-day and 1-year mortality risk after ﬁrst
time hospitalisation for MI between 1999–2003 and 2004–
2008. Part of this reduction could be due to a decrease in
time to treatment. When comparing with this study, one
should keep in mind that we did not include patients with
STEMI who are included in Schmidt et al’s study and that
these patients have a succinct treatment path with the
need for more urgent treatment. There seems to be no
other nationwide studies on trends in time from diagnosis
to invasive treatment; however, in 2009 Bradley et al19
reported a decrease in door-to-balloon time for patients
with STEMI after enrolment in a national quality cam-
paign with the aim to reduce the door-to-balloon time to
less than 90 min for this group.
We did ﬁnd a signiﬁcant decline in time for CAG and
PCI corresponding to the implementation of the ﬁxed
treatment protocol for NSTEMI. However, for both
NSTEMI and unstable angina, we found a steady
increase in treatment rate from 2001 onwards and for
NSTEMI a steep increase in probability already in 2008.
This indicates that focus on improvement on time to
invasive examination and treatment is not new.
Furthermore, the treatment protocols were ﬁrst imple-
mented during 2009, but they were already discussed in
2008 and this could have led to early implementation
and hence an increase in speed of invasive examination
and treatment before the actual implementation. In this
time period, there seemed to be a general agreement
on the beneﬁts of an invasive strategy versus medical
management for patients with NSTEMI.20 21 However,
the optimal timing of invasive interventions was not
clearly agreed on. Mehta et al published in 2009 their
results from the large TIMACS trial which included 3031
patients with unstable angina or NSTEMI. They found a
signiﬁcantly lower risk of death, MI or stroke at
6 months for high-risk patients when comparing an early
(less than 24 h) with a delayed strategy (more than
36 h). Furthermore, they found no safety issues related
to the early strategy.22 This shows the importance of
early invasive treatment; however, these results only
reﬂect the difference between very early and early inva-
sive intervention which is a slightly another discussion
than ours. In 2010 a meta-analysis was published
combining four trials which concluded that early angiog-
raphy and if relevant treatment for patients with
NSTEMI reduces the risk of recurrent ischaemia and
shortens hospital stay.23 These results were, however, not
reﬂected in the European Society of Cardiology guide-
lines until 2011.4 However, the previous guideline from
2007 (ibid, p.27) also stated:“…Accordingly, currently
available evidence does not mandate a systematic
approach of immediate angiography in NSTE-ACS
patients stabilized with a contemporary pharmacological
approach. Likewise, routine practice of immediate trans-
fer of stabilized patients admitted in hospitals without
onsite catherization facilities is not mandatory, but
should be organized within 72 h”.7 We found that the
number of patients receiving the recommended invasive
examination and treatment within the recommend time
frame increased from 2001 to 2009; however, a large
group of patients still received no invasive investigation
or were treated later than the guideline recommends in
2009. This patient group consists of three possible
groups: patients that do not have the disease in question
due to lack of validity of data (see later discussion of
Strengths and Weaknesses), patients who are too ill to
be treated and patients who receive a less than optimal
treatment. The basic idea behind the ﬁxed treatment
protocol, that is same treatment for patients presenting
with the same clinical symptoms irrespective of when or
where patients come in contact with the healthcare
system should ensure that the latter group is proportion-
ally smaller in 2009 than in 2001. However, there could
still be patients who do not receive optimal treatment
and unexplained variation between hospitals. Therefore,
monitoring by health authorities is of great importance.
Strengths and weaknesses
The primary strength of this study is the large unse-
lected patient population, as it covers all patients admit-
ted with ﬁrst time ACS during the period from 2001 to
2009 in Denmark. The patients were identiﬁed in the
NPR; however, this means that we do not have informa-
tion on biomarkers but solely rely on the correctness on
what is registered in the NPR. We excluded outpatients
and patients with a diagnosis from an emergency room
which was not veriﬁed in a ward subsequently; however,
especially the unstable angina diagnosis is still problem-
atic. Thus, it has been found that the positive predictive
value of unstable angina for patients discharged from a
ward only seems to be around 40%.12 Therefore, one
reason for the lack of effect of the ﬁxed treatment proto-
cols for this group of patients could be that a substantial
part of this group does not have unstable angina. The
data in the NPR allowed us to follow patients through
the course of diagnosis and treatment path, and we uti-
lised this to change patients’ diagnoses after the CAG in
case another diagnosis was registered at this point in
time. This was carried out in order to imitate the clinical
situation. At CAG 8412 patients had a diagnosis other
than ACS. The largest group was 3230 patients with
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angina no speciﬁcation. This group of patients could
potentially be patients with unstable angina; however;
including this group did not change the conclusions
(analysis not shown). We had information on the spe-
ciﬁc hour of admission and used this information to cal-
culate time to treatment. Although the validity of this
information can be questioned, we used it in order to
calculate the time as precisely as possible. We only
included treatment and examination within 60 days as
ACS is an acute disease for which treatment, if relevant,
should be initiated as soon as possible. We analysed our
data by use of statistical methods that accounted for the
competing risk of death, which is very important when
we estimate trends in time to treatment in a population
with a high risk of death. However, we do not know
whether patients who died were not treated because the
risk of invasive examination and treatment was deemed
too high, or because the treatment was not considered
relevant. Our analysis showed that the group of patients
not receiving CAG was reduced in the period from 2001
to 2009, which was primarily due to an increase in exam-
ination of elderly patients (analysis not shown). We also
included information on the number of occluded vessels
and LMCA involvement as a measure of the extension
and severity of the disease in the analysis. This informa-
tion was only available for 84.7% and 82.1% of the
patients, and especially patients from 2001 and 2002 had
missing information on this variable. However, we have
no reason to believe that this missing data should be
non-random and related to time to treatment.
Furthermore, we did not use age-standardised data in
the trend analyses because the ﬁxed treatment protocols
include all patient groups. However, we tested whether
there was an effect of the treatment protocols in the
Fine-Gray model which adjusted for age, gender, LMCA
involvement and number of occluded vessels. The ana-
lyses showed that these variables did not change the
effect of the treatment protocols. It should also be
noticed that we did not include patients who died
before arrival to a hospital as these patients are not
included in the NPR. It should also be noticed that our
study is an observational trend study and we cannot
exclude that other organisational or treatment factors
than the introduction of the ﬁxed treatment protocol
have contributed to the observed reduction in time to
examination and treatment. This study only evaluates
the immediate effects of the ﬁxed treatment protocols;
however, a longer follow-up would also be of interest.
In conclusion, this study contributes to the interpret-
ation of the recent decline in mortality after hospitalisa-
tion for MI by showing a contemporary increase in the
proportion of patients receiving a CAG and PCI as well
as an increase in the probability of patients receiving
CAG and PCI within the recommended time. The study
also suggest that the introduction of ﬁxed treatment pro-
tocols with a recommended maximum time from diag-
nosis to invasive examination and treatment may have
impacted on time to treatment as more patients receive
a CAG and PCI within the time limit of 3 days around
the time of the introduction of the protocols.
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